🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mark R. Albertini

University of Wisconsin–Madison

ORCID: 0000-0002-6499-517X

Also affiliated with University of Wisconsin Carbone Cancer Center, William S. Middleton Memorial Veterans Hospital

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2”.

Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3294

N/A

0.874DataRank · unranked

23 citations

Igor B. Kuznetsov, Erik A. Ranheim, Jun S. Wei, Sivasish Sindiri, Berkley E. Gryder +13 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535

N/A

0.520DataRank · unranked

31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9591

N/A

0DataRank · unranked

2 citations

Zachary S. Morris, Jacquelyn A. Hank, Erik A. Ranheim, Cindy Zuleger, Kimberly A. McDowell +13 more

862 Administration of intratumoral hu14.18-IL2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0862

N/A

0DataRank · unranked

0 citations

Cindy Zuleger, Erik A. Ranheim, Oyewale Shiyanbola, Andrew T. Kosharek, Paul M. Sondel +12 more

Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy

Pigment Cell & Melanoma Research(2023)10.1111/pcmr.13109

N/A

0DataRank · unranked

24 citations

Yeonhee Park, Yusuf M. Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair +3 more

NK cells propagate T cell immunity following in situ tumor vaccination

Cell Reports(2023)10.1016/j.celrep.2023.113556

N/A

0DataRank · unranked

16 citations

Justin C. Jagodinsky, Jessica M. Vera, Paul A. Clark, Cindy Zuleger, Amy K. Erbe +11 more

Development of a next-generation sequencing protocol for the canine T cell receptor beta chain repertoire

Veterinary Immunology and Immunopathology(2023)10.1016/j.vetimm.2023.110702

N/A

0DataRank · unranked

3 citations

Rene Welch, Irene M. Ong, Michael A. Newton, David M. Vail, Mark R. Albertini +1 more

Surrogate selection oversamples expanded T cell clonotypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.07.13.548950

N/A

0DataRank · unranked

0 citations

Yumin Lian, Cindy Zuleger, Richard J. Albertini, Mark R. Albertini, Michael A. Newton +1 more

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

Melanoma Research(2024)10.1097/cmr.0000000000000975

N/A

0DataRank · unranked

7 citations

Cindy Zuleger, Erik A. Ranheim, Oyewale Shiyanbola, Paul M. Sondel, Zachary S. Morris +9 more

In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma

PLoS ONE(2025)10.1371/journal.pone.0330200

N/A

0DataRank · unranked

0 citations

Cindy Zuleger, William S. Glass, Jens C. Eickhoff, Paul M. Sondel, David M. Vail +2 more

FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls

Seminars in Nuclear Medicine(2020)10.1053/j.semnuclmed.2020.06.001

N/A

0DataRank · unranked

37 citations

Daniel T Huff, Robert Jeraj, Mark R. Albertini, Steve Y. Cho

SatTCR: a pipeline for performing saturation analysis of the T cell receptor repertoire and a case study of a healthy canine

MethodsX(2025)10.1016/j.mex.2025.103733

N/A

0DataRank · unranked

0 citations

Cindy Zuleger, Michael A. Newton, David M. Vail, Mark R. Albertini, Irene M. Ong +1 more

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

PLoS ONE(2021)10.1371/journal.pone.0255798

N/A

0DataRank · unranked

39 citations

Ian R. Marsh, Michelle Turek, Joseph J. Grudzinski, Eduardo Aluicio‐Sarduy, Jonathan W. Engle +13 more